A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Which Contained a Platinum Agent.

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2005
This article has no abstract
Epistemonikos ID: 7cc7778c8db8cb20aa9741d8732fda5d532d7350
First added on: Apr 17, 2025